2023/01/12

PEPTALK 出展・発表のお知らせ

味の素バイオ・ファーマサービスは、2023年1月16日(月)～20日(金)開催のPEPTALKに出展いたします。

PEPTALKでは、抗体探索、タンパク質工学、二重特異性抗体、新たな免疫療法、タンパク質凝集、機械学習、細胞および遺伝子治療、タンパク質発現、精製および生産等について、世界的に著名な講演者による講演、展示・口頭/ポスターによる最先端技術の紹介、魅力的なネットワーキングイベントが行われます。

味の素バイオ・ファーマサービスは、展示ブースにて、サービス・技術の紹介を行う他、口頭2件、ポスター３件の発表を行います。

皆様のご来場をお待ちしております。

演題・発表者	Introduction of Biopharmaceutical Development and CORYNEX® Technology to Address Challenges in Manufacturing Hayato Nagano, Ajinomoto Co., Inc.
要旨	Ajinomoto Bio-Pharma Services, as a fully integrated contract development and manufacturing organization (CDMO), offers a broad range of innovative platform technologies and end-to-end solutions for biopharmaceutical development and manufacturing. In this presentation, we will introduce our CDMO capability and CORYNEX® protein expression platform technology for biopharmaceuticals, which together can improve drug substance manufacturing.
日時・場所	2023年1月18日(水) 12:45 Aqua Salon AB

演題・発表者	Novel Format Conjugates and Multi-Specific Antibodies Produced by Chemical Site-Specific Conjugation: AJICAP® Yutaka Matsuda, Ajinomoto Co., Inc.
要旨	Site-specific chemical conjugation technology (termed AJICAP®) is a simplified manufacturing process without using antibody engineering. We attempted to use site-specific conjugation technology to produce bispecific and trispecific antibodies with a new shape. The development of the unique methodology to produce homogeneous DAR = 1 conjugates enabled the production of homogeneous multispecific antibodies without a difficult purification process. Initial applications of AJICAP® technology to novel format conjugates are also discussed.
日時・場所	2023年1月19日(木) 9:50 Aqua Salon D

演題・発表者	From peptides and small proteins to mAb, Ajinomoto’s proprietary microbial platform for pharmaceutical protein production Kazuo Yamagishi, Ajinomoto Co., Inc.
要旨	We will introduce the cutting-edge technologies of Ajinomoto’s proprietary microbial secretory protein production. CORYNEX® : A bacterial recombinant protein expression system for antibody fragments and scaffolds. Endotoxin-free platform using Gram-positive bacteria as host cells. TALAMAX® : A system for the production of antibodies and antibody fragment fusion proteins using microbe. Compared to conventional antibody production using mammalian cells, culture time is half and the cost of raw materials is reduced to 1/10.
ポスターカテゴリー	C5B: Recombinant Protein Expression and Production

演題・発表者	ADC Therapeutic Window Enhancement Based on the Site-Specific Conjugation Platform: AJICAP® Conjugation Hiroki Imai, Ajinomoto Co., Inc.
要旨	The chemical conjugation of antibodies in a site-directed manner remains an area of great interest and active efforts within the ADC community. In this poster, we present a novel platform named “AJICAP®” for the chemical and site-selective conjugation of native antibodies. Recent enhancements of the AJICAP® platform and conjugation at an additional Lys residue will be introduced. Therapeutic window enhancement will be also discussed.
ポスターカテゴリー	C2C: Safety and Efficacy of Bispecific Antibodies, ADCs and Combination Therapy

演題・発表者	Novel Format Conjugates and Multi-Specific Antibodies Produced by Chemical Site-Specific Conjugation: AJICAP® Yutaka Matsuda, Ajinomoto Co., Inc.
要旨	A site-specific chemical conjugation is a well-known approach to producing homogeneous ADC with a simplified manufacturing process without an antibody engineering process. Aiming versatile manufacturing of multispecific antibodies, we attempted to apply site-specific conjugation technology to produce bispecific and trispecific antibodies as novel formats. Furthermore, the development of a unique methodology to produce homogeneous DAR = 1 conjugates enabled the production of homogeneous multispecific antibodies without a complicated purification process.
ポスターカテゴリー	C2C: Safety and Efficacy of Bispecific Antibodies, ADCs and Combination Therapy